secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031141
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction
---------------------------------------------------------------------------

- KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.
- FDA de-novo marketing authorization for kidneyintelX.dkd received June 2023 for use in type 2 diabetes patients.
- Outcomes data from >2,500 patients showed sustained reduction in eGFR decline and improved diabetes/cardiovascular management.
- Current enrollment >9,000 patients with type 2 diabetes and CKD for ongoing clinical utility and outcomes studies.
- Guideline emphasizes risk prediction and personalized treatment; Renalytix aims to expand evidence base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/0000950170-24-031141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/rnlx-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer